Expression of IGFBP2 mRNA in glioblastoma and its clinical implication

Abstract

Objective The present study is to investigate the expression of IGFBP2 mRNA in glioblastoma (GBM) and its clinical relevance. Methods Tissue microarrays and RNAscope in situ hybridization were used to detect the expression of IGFBP2 mRNA in 128 cases of GBM tumor tissues. The correlations between the expression and clinicopathological parameters as well as some other biomarkers were analyzed. Results High expression of IGFBP2 mRNA was observed in 22.7% of tumor tissues tested. No expression of IGFBP2 mRNA was detected in normal or edematous tissues. High expression of IGFBP2 mRNA was negatively correlated with patients’ KPS scores and IDH1 mutation (P=0.007, 0.033). The high expression rate of IGFBP2 transcript in primary GBM was significantly higher than that in secondary GBM (P=0.040). Kaplan-Meier analysis showed that the patients with high expression of IGFBP2 mRNA had shorter survival time than those with low expression of IGFBP2 mRNA(P<0.001). Both univariate and multivariate regression indicated that the expression of IGFBP2 transcript level was an independent prognostic factor. Conclusion IGFBP2 mRNA expression status detected by RNAscope in situ hybridization is an independent prognostic biomarker in glioblastoma, and it might be served as a prognostic indicator for glioblastoma patients. Key words: Glioblastoma; RNA in situ hybridization (RISH); IGFBP2; Biomarker